IGF-DES
Truncated insulin-like growth factor-1 analogue discussed for localized growth factor signaling in experimental and performance-related settings.
This page is for general educational and informational purposes only. It is not medical advice and does not replace professional medical judgment. Always consult a qualified clinician before starting, stopping, or changing any medication or protocol.
Overview
IGF-DES (des(1-3) IGF-1) is a truncated analogue of insulin-like growth factor-1 designed to alter receptor interactions and local tissue activity.
It is primarily encountered in experimental and performance-related discussions, not routine clinical endocrinology.
Mechanism of action
Removal of the first three amino acids reduces binding to IGF-binding proteins, potentially increasing local availability at IGF-1 receptors in certain tissues.
Indications and use context
IGF-DES has been explored conceptually for localized growth or repair, but it is not an approved therapy for these indications.
Non-regulated use is associated with uncertainty around benefits and risks.
Safety and side effects
Manipulating IGF signaling may influence growth, metabolism, and potentially oncologic risk.
Formal safety data for IGF-DES in humans are limited.
Pharmacology and dosing considerations
IGF-1 DES (1-3) is a truncated, short-acting analogue (half-life ~20-30 mins) used for site-specific growth.
Route: Intramuscular (IM) injection into the target muscle.
Protocol structure and dosage:- Dosage: 50 mcg to 100 mcg per administration (often split bilaterally).
- Timing: Pre-workout or intra-workout due to rapid onset and clearance.
- Frequency: Administered only on training days.
This peptide is used to target specific muscle groups ("site enhancement") rather than systemic growth.
Formulations and combinations
IGF-DES may appear in catalogs as a lyophilized peptide and is sometimes mentioned alongside growth hormone, IGF-1 LR3, or other anabolic agents in performance discussions.
Research and evidence snapshot
Evidence consists mainly of preclinical work and limited quasi-clinical use; large randomized trials are lacking.
Frequently asked questions
Future FAQs may address how experimental IGF analogues compare conceptually with regulated therapies and why their use is restricted in sport. Answers will remain educational and non-prescriptive.
Sport & Anti-Doping Warning
Truncated IGF-1 analogues such as IGF-DES fall under the same peptide hormone/growth factor prohibition as other IGF derivatives, and are frequently cited in discussions of designer growth-factor doping.
From an anti-doping standpoint, IGF-DES is treated similarly to other unapproved IGF analogues regardless of how localized or 'site-specific' its proposed action is.
Comments
Loading comments...
Get the Standard Protocols.
Join 12,000+ researchers. Receive weekly breakdowns of new compounds, safety data updates, and source verification reports.